Piptaz

# Piptaz ## Overview - **Classification**: Penicillin antibiotic, Beta-lactamase inhibitor combination - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam inactivates bacterial beta-lactamases, protecting piperacillin from degradation. ## Primary Indications 1. **Nosocomial Pneumonia** - Including ventilator-associated pneumonia. 2. **Complicated Intra-abdominal Infections** - Peritonitis, appendicitis with rupture. 3. **Skin and Skin Structure Infections** - Cellulitis, abscesses, diabetic foot infections. 4. **Gynecological Infections** - Postpartum endometritis, pelvic inflammatory disease. 5. **Febrile Neutropenia** - Empiric treatment for bacterial infections. 6. **Bacteremia** - Associated with any of the above infections. ## Adult Dosing ### Standard Dosing **Most Infections (e.g., cIAI, SSTI)** - **Dose**: **3.375 g IV** (piperacillin 3 g / tazobactam 0.375 g) - **Frequency**: Every 6 hours - **Route**: IV infusion over 30 minutes (or 3-4 hours for extended infusion) - **Duration**: 5-14 days, dependent on infection severity and source control. **Nosocomial Pneumonia & Febrile Neutropenia** - **Dose**: **4.5 g IV** (piperacillin 4 g / tazobactam 0.5 g) - **Frequency**: Every 6 hours - **Route**: IV infusion over 30 minutes (or 3-4 hours for extended infusion) - **Maximum Dose**: **18 g/day** of piperacillin (equivalent to 20.25 g piperacillin/tazobactam) ### Dose Adjustments - **Renal Impairment**: Dose reduction is essential. - CrCl > 40 mL/min: No adjustment. - CrCl 20-40 mL/min: **2.25 g IV** every 6 hours. - CrCl < 20 mL/min: **2.25 g IV** every 8 hours. - Hemodialysis: **2.25 g IV** every 8 hours, with an additional **0.75 g IV** (piperacillin 0.67 g / tazobactam 0.08 g) post-dialysis. - **Hepatic Impairment**: No specific dose adjustment, but monitor for adverse effects. - **Elderly Patients**: Adjust based on renal function. Elderly may have reduced renal clearance. ## Pediatric Dosing ### Neonates (0-28 days) - **Special Notes**: Limited data, generally avoid if possible. If necessary for specific severe infections, use with extreme caution. Prolonged intervals due to immature renal function. - **Dose**: **75-100 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 8-12 hours - **Maximum**: Not well-established, careful monitoring required. ### Infants (1-12 months) - **Indication**: Most susceptible infections. - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6 or 8 hours - **Maximum**: **4.5 g/dose** (piperacillin 4 g / tazobactam 0.5 g) ### Children (1-12 years) - **Indication**: Complicated appendicitis or other intra-abdominal infections. - **Dose**: **100 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 8 hours - **Maximum**: **4.5 g/dose** (piperacillin 4 g / tazobactam 0.5 g) - **Indication**: Other infections (e.g., pneumonia, SSTI). - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6-8 hours - **Maximum**: **4.5 g/dose** (piperacillin 4 g / tazobactam 0.5 g) - **Indication**: Febrile neutropenia. - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6 hours - **Maximum**: **4.5 g/dose** (piperacillin 4 g / tazobactam 0.5 g) ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Maximum**: **18 g/day** of piperacillin (equivalent to 20.25 g piperacillin/tazobactam) ## Safety Information ### Contraindications - **Absolute**: History of severe allergic reaction (e.g., anaphylaxis, Stevens-Johnson Syndrome) to penicillins, cephalosporins, or other beta-lactam antibiotics. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, rash, nausea, constipation, headache, insomnia. - **Common (1-10%)**: Vomiting, dyspepsia, pruritus, phlebitis at injection site, elevated liver enzymes (ALT, AST). - **Serious but Rare**: Anaphylaxis, Clostridioides difficile infection (CDI), seizures (especially with high doses or renal impairment), thrombocytopenia, leukopenia, interstitial nephritis. ### Key Drug Interactions - **Aminoglycosides**: Inactivation of aminoglycoside when mixed. Administer separately; do not mix in the same IV solution or Y-site. - **Methotrexate**: Decreased renal clearance of methotrexate. Monitor methotrexate levels and for toxicity; consider dose adjustment. - **Probenecid**: Inhibits renal excretion of piperacillin/tazobactam. Increases and prolongs serum levels. - **Vecuronium**: Prolongs neuromuscular blockade. Monitor for increased or prolonged effects. ## Monitoring & Follow-up - **Before Treatment**: Culture and susceptibility tests, renal function (serum creatinine, CrCl). - **During Treatment**: - Renal function (CrCl, serum creatinine) daily/every other day, especially in critically ill or renally impaired patients. - Complete Blood Count (CBC) with differential, especially with prolonged therapy (>10-14 days). - Liver function tests (LFTs) if prolonged therapy or pre-existing hepatic impairment. - Monitor for signs of superinfection (e.g., C. difficile diarrhea). - **Clinical Signs**: Watch for allergic reactions (rash, dyspnea), signs of bleeding, new-onset seizures, or changes in neurological status. ## Clinical Pearls - 💡 **Extended infusion (e.g., 3-4 hours)** is often preferred for critically ill patients to optimize pharmacodynamics (time above MIC). - 💡 **Always adjust dose for renal impairment** to prevent drug accumulation, which can lead to neurotoxicity (seizures). - 💡 **Do NOT mix with aminoglycosides** in the same IV solution or line due to physical inactivation. Administer separately. - 💡 Monitor for **Clostridioides difficile-associated diarrhea (CDAD)**, which can occur even after treatment discontinuation. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.